Novartis To Bolster U.S. Sales Force In Anticipation Of 2007 Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss firm says it will add two cardiovascular field forces in the U.S. in 2006.
You may also be interested in...
Novartis/Speedel Anti-Hypertensive Rasilez Could Reach Market By Year-End
NDA for the oral renin inhibitor, submitted in the first quarter, seeks monotherapy and combination treatment claims.
J&J Pharma Sales Force Reduced As Part Of Efficiencies Program
Firm says it has implemented a "modest" sales force reduction.
Novartis' Galvus NDA Follows Close On The Heels Of Merck's Januvia
The likely late November user fee date for Novartis' DPP-IV inhibitor vildagliptin is mere weeks behind that for sitagliptin.